Safety and tolerability of Nilotinib in patients with Huntington’s disease
Objective: To investigate the safety and tolerability of nilotinib, an FDA-approved drug for leukemia, in individuals with Huntington’s disease (HD). Background: Previous clinical studies in…Perceptions of Palliative Care in Huntington’s Disease
Objective: This study aims to identify perceptions of palliative care in Huntington’s Disease (HD), palliative care needs of patients with HD, and at what point…An unusual cause of choreoathetosis: PRES and Goodpasture’s Syndrome
Objective: Our aim is to shed light on an usual cause of choreoathetosis in a medically complex case. Background: Goodpasture’s syndrome(GBS) is a rare autoimmune…Long-term Deutetrabenazine Safety on Motor, Psychiatric, and Cognitive Measures in Individuals With Chorea Associated With Huntington Disease
Objective: To evaluate long-term deutetrabenazine safety on motor, psychiatric, and cognitive measures in participants with chorea associated with Huntington disease (HD). Background: Deutetrabenazine, a vesicular…Evaluation of the QTc prolongation risk of deutetrabenazine
Objective: To assess QTc prolongation risk of deutetrabenazine and its active metabolites by conducting exposure-QTc interval modeling, and to predict QTc prolongation in both CYP2D6…Proof-of-concept study testing bevantolol (SOM3355) as treatment of chorea in Huntington’s disease
Objective: Proof-of-concept phase IIa study assessing bevantolol (SOM3355) efficacy and safety in reducing chorea in Huntington’s disease (HD). Background: Bevantolol hydrochloride, a β1‐adrenoceptor antagonist used…Diabetes Mellitus in Huntington’s disease. The Argentinean perspective
Objective: to compare the prevalence of diabetes mellitus (DM) in a self-reported series of local Huntington disease (HD) participants in the ENROLL-HD registry with the…Characterizing US Healthcare Delivery in Huntington’s Disease (HD)
Objective: The HD-Net research survey aimed to assess care patterns among practice types in the U.S., to identify gaps in the provision of HD care.…Healthcare utilization in individuals with late onset versus adult-onset Huntington’s disease
Objective: To assess healthcare utilization (HCU) among patients (pts) with late-onset Huntington’s disease (LoHD) versus adult-onset HD (AoHD) and non-HD controls. Background: HD typically manifests…Burden of illness among US Medicare beneficiaries with late-onset Huntington’s disease
Objective: Examine healthcare resource utilization (HRU) and costs among US Medicare beneficiaries with late-onset Huntington’s disease (LoHD). Background: Huntington’s disease (HD) is a genetic, neurodegenerative…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 9
- Next Page »